Cite
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.
MLA
Self, Wesley H., et al. “Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.” JAMA: Journal of the American Medical Association, vol. 329, no. 14, Apr. 2023, pp. 1170–82. EBSCOhost, https://doi.org/10.1001/jama.2023.3546.
APA
Self, W. H., Shotwell, M. S., Gibbs, K. W., de Wit, M., Files, D. C., Harkins, M., Hudock, K. M., Merck, L. H., Moskowitz, A., Apodaca, K. D., Barksdale, A., Safdar, B., Javaheri, A., Sturek, J. M., Schrager, H., Iovine, N., Tiffany, B., Douglas, I. S., Levitt, J., & Busse, L. W. (2023). Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA: Journal of the American Medical Association, 329(14), 1170–1182. https://doi.org/10.1001/jama.2023.3546
Chicago
Self, Wesley H., Matthew S. Shotwell, Kevin W. Gibbs, Marjolein de Wit, D. Clark Files, Michelle Harkins, Kristin M. Hudock, et al. 2023. “Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.” JAMA: Journal of the American Medical Association 329 (14): 1170–82. doi:10.1001/jama.2023.3546.